Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and efficacy of melatonin supplementation in CKD and ESRD
patients with sleep disorders to reduce sleep latency times, the number of apnea/hypopneic
episodes, and prolong duration in rapid eye movement (REM) sleep in CKD and ESRD patients
with sleep disordered breathing.